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Introduction
A protein-truncating variant (rs72613567:TA), encoding the hepatic lipid droplet protein hydroxysteroid 17-β 
dehydrogenase 13 (HSD17B13), was recently reported to reduce risks of alcoholic and nonalcoholic cirrhosis (1, 
2), fibrosis (1–3), and histologic signs of inflammation and ballooning (3). The variant does not seem protective 
against steatosis (1–3). The mechanism(s) via which the variant confers protection to liver disease are unclear.
Until now, 15 17β-hydroxysteroid dehydrogenases (HSD17Bs) have been identified in humans. 
HSD17B1–HSD17B6 regulate sex steroid metabolism, while others are involved in regulation of  fatty 
and bile acid metabolism and cholesterol biosynthesis (4, 5). HSD17B13 is a lipid droplet–associated 
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clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was 
significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in 
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protein (3, 6), mainly expressed in the liver (7). It is a target gene for the insulin-regulated lipogenic 
transcription factor steroid responsive element–binding protein 1c (SREBP1c) (8) and upregulated in 
the liver in human nonalcoholic fatty liver disease (NAFLD) (6). This could be secondary to hyperin-
sulinemia and increased de novo lipogenesis (DNL) in NAFLD associated with insulin resistance (9) 
or a consequence of  HSD17B13, because overexpression of  this protein caused steatosis in mice and 
increased lipid droplet size and number in cultured human hepatocytes (6). Mouse data are, however, 
contradictory as knockout of  HSD17B13 induced steatosis in male mice (10). Furthermore, in a recent 
study neither stable overexpression nor silencing of  HSD17B13 altered lipogenesis in HepG2 cells (2). 
Intracellular triglyceride content was unaltered in oleic acid treated cell lines overexpressing HSD17B13 
isoforms A and D, i.e., the transcripts encoding full-length (predominant in reference allele homozygotes 
[T/T]) and prematurely truncated (predominant in alternate allele homozygotes [TA/TA]) proteins (1). 
Whether the gene variant alters pathways contributing fatty acids to intrahepatic triglycerides (IHTG) in 
humans has not been investigated.
HSD17B3 has enzymatic activity against several lipid substrates that have been implicated in lip-
id-mediated inflammation, including metabolites originating from phospholipids (1). Each of  the recently 
described major genetic variants increasing the risk of  NAFLD fibrosis influence metabolism of  hepatic 
phospholipids. Patatin-like phospholipase domain–containing protein 3 (PNPLA3) functions in fatty acid 
remodeling by transferring polyunsaturated fatty acid from triglycerides to phospholipids (11). Loss of  
this function results in accumulation of  polyunsaturated fatty acids in triglycerides in the mouse liver 
(11) and the human liver of  carriers of  the PNPLA3 I148M gene variant (12). Impaired incorporation of  
polyunsaturated fatty acids into hepatic triglycerides, phospholipids, and cholesterol esters characterizes 
transmembrane 6 superfamily member 2 (TM6SF2) E167K variant carriers with NAFLD (13). Mem-
brane-bound O-acyltransferase domain containing 7 (MBOAT7) is a lysophosphatidylinositol acyltrans-
ferase, which catalyzes acyl-chain remodeling of  phosphatidylinositols and alters plasma and liver phos-
phatidylinositol concentrations (14, 15).
In the present study, we wished to characterize the human liver lipidome and transcriptome in car-
riers and noncarriers of  the HSD17B13 variant (rs72613567:TA). Furthermore, as there are no data on 
whether the HSD17B13 variant influences the major pathways contributing fatty acids to IHTG synthesis 
in humans or insulin sensitivity, we quantified DNL using deuterated water, insulin sensitivity using the 
euglycemic insulin clamp technique, and rates of  basal and insulin-stimulated lipolysis using deuterated 
glycerol in carriers and noncarriers of  the HSD17B13 variant.
Results
Characteristics of the study groups
Clinical characteristics of  the HSD17B13 genotype groups with liver histology data are shown in Table 1. The 
groups were similar with respect to age, sex, and BMI (Table 1). The TTA/TATA group had lower aspartate 
aminotransferase (AST) (29.5 ± 1.2 vs. 36.7 ± 2.6 IU/L, P < 0.05, Table 1) compared with the TT group. 
Concentrations of  fasting glucose, insulin, and lipids in the circulation as well as distributions of  PNPLA3, 
TM6SF2, and MBOAT7 genotypes were comparable among the HSD17B13 genotype groups (Table 1).
Liver histology. Macrovesicular steatosis and necroinflammatory activity were similar between the 
groups (Figure 1 and Table 1). The prevalence of  fibrosis was significantly lower in the TTA/TATA group 
as compared with the TT group (25.0% vs. 42.4%, P < 0.05, Figure 1 and Table 1). There were no subjects 
with significant fibrosis (fibrosis stage ≥2) in the TTA/TATA group as compared with the 6.8% of  the sub-
jects with significant fibrosis in the TT group (P < 0.05, Table 1).
Clinical characteristics of  the subjects in whom pathways of  hepatic triglyceride synthesis and insulin 
sensitivity were measured are shown in Supplemental Tables 1–5 (supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.132158DS1).
Lipidomic analysis
The log2 fold changes in liver lipids in the TTA/TATA group as compared with the TT group are shown in 
Figure 2. Among all lipids, exclusively phospholipids were significantly altered. Specifically, concentrations 
of  phosphatidylcholines (PCs), such as PC(p16:0/16:0), PC(44:5e), PC(36:2e), and PC(34:3), and phos-
phatidylethanolamines (PEs), such as PE(p16:0/18:1), PE(34:0) and PE(36:3), were increased in the liver 
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in the TTA/TATA group as compared with the TT group (Figure 2). The increases in individual liver PC 
species in the TTA/TATA versus the TT group were virtually uniform and did not depend on the number 
of  double bonds or carbons in a given species (Supplemental Figure 1, A and B). In liver PEs, the greatest 
increases in the TTA/TATA versus the TT group were in species with 0–4 double bonds and 32–40 carbons 
(Supplemental Figure 1, C and D).
Table 1. Clinical characteristics of the study subjects with liver histology data grouped by the HSD17B13 
genotype at rs72613567
TT (n = 118) TTA/TATA (n = 84)
Age (yr) 46.1 ± 0.8 47.0 ± 1.0
Sex (% women) 80.5 76.2
BMI (kg/m2) 41.5 ± 0.7 42.1 ± 0.8
Waist circumference (cm) 121.1 ± 1.5 122.6 ± 1.8
fP-Glucose (mmol/L) 5.5 (5.1–5.9) 5.6 (5.2–5.8)
HbA1C (%) 5.5 (5.2–5.7) 5.6 (5.4–5.8)
HbA1C (mmol/mol) 36.6 (33.3–41.0) 37.7 (35.5–39.9)
fS-Insulin (mU/L) 11.2 (6.9–17.4) 11.1 (7.7–16.2)
HOMA-IR 2.9 (1.7–4.5) 2.9 (1.8–4.1)
fP-Triglycerides (mmol/L) 1.09 (0.82–1.45) 1.11 (0.85–1.63)
fP-HDL cholesterol (mmol/L) 1.17 (1.02–1.49) 1.21 (0.99–1.48)
fP-LDL cholesterol (mmol/L) 2.7 ± 0.1 2.9 ± 0.1
P-AST (IU/L) 36.7 ± 2.6 29.5 ± 1.2A
P-ALT (IU/L) 44.4 ± 4.2 37.8 ± 3.2
P-ALP (IU/L) 73.4 ± 3.8 77.0 ± 4.7
P-GGT (IU/L) 50.2 ± 7.3 44.3 ± 4.9
P-Albumin (g/L) 38.7 ± 0.3 38.3 ± 0.3
B-Platelets (×109/L) 250 ± 5 255 ± 7
Macrovesicular steatosis (%) 5 (0–20) 5 (0–20)
Steatosis score (%, 0/1/2/3) 50/38/6/7 43/45/8/4
Activity grade (%, 0/1/2/3/4) 93/4/4/0/0 93/5/3/0/0
 Ballooning (%, 0/1/2) 96/4/0 95/5/0
 Inflammation (%, 0/1/2) 93/7/0 95/5/0




PNPLA3 genotype (%, CC/CG/GG) 58/34/7 54/40/6
TM6SF2 genotype (%, CC/CT/TT) 86/13/1 91/8/1
MBOAT7 genotype (%, CC/CT/TT) 37/51/12 33/47/20
Data are shown as percentage and mean ± SEM or median (25th–75th percentile), as appropriate. AP ≤ 0.05. fP, fasting 
plasma; fS, fasting serum; P, plasma; B, blood.
Figure 1. Decreased hepatic fibrosis in carriers of the HSD17B13 rs72613567 variant. (A) The percentage of subjects with steatosis (macrovesicular steato-
sis, ≥5%). (B) The percentage of subjects with necroinflammatory activity (activity grade, ≥1). (C) The percentage of subjects with fibrosis (fibrosis stage, 
≥1) in the TT (n = 118) and TTA/TATA (n = 84) groups, as determined histologically using the SAF score. Distributions were tested using Pearson’s χ2 test. 
Black bars = TT; green bars = TTA/TATA. *P < 0.05.
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Hepatic transcriptome
In hepatic transcriptome analysis, a total of  274 genes were differentially expressed (q < 0.05) in the TTA/
TATA group as compared with the TT group (Figure 3A). Among these 274 genes, 166 were downregulat-
ed (Supplemental Table 6) and 108 were upregulated (Supplemental Table 7).
Individual genes that were differentially expressed in the TTA/TATA group as compared with the TT 
group were analyzed using gene set enrichment analysis of  gene ontology (GO) pathways. A total of  254 
gene sets were downregulated (Supplemental Table 8) and 2 pathways were upregulated in the TTA/TATA 
group as compared with the TT group (Supplemental Table 9). The top 20 most significantly downregulated 
gene sets in the TTA/TATA group as compared with the TT group are visualized as an enrichment map in 
Figure 3B. These include several inflammation-related gene sets, such as Activation of  immune response (q 
< 2.16 × 10–6), Positive regulation of  innate immune response (q < 4.66 × 10–6), Activation of  innate immune 
response (q < 1.61 × 10–5), and Positive regulation of  defense response (q < 3.90 × 10–5) (Figure 3B). Down-
regulated genes that were enriched in these gene sets include arachidonate 5-lipoxygenase (ALOX5), hypox-
ia-inducible factor 1 subunit α (HIF1A) and TGF-β2 (TGFB2) (Supplemental Figure 2). Upregulated genes 
in the TTA/TATA group as compared with the TT group included lipin 3 (LPIN3) (Supplemental Table 7).
RNA-seq was followed by quantitative PCR (qPCR) analyses, in which downregulation of  ALOX5 
(0.77 ± 0.04 vs. 1.00 ± 0.06 AU, P < 0.01) and TGFB2 (0.79 ± 0.05 vs. 1.00 ± 0.06 AU, P < 0.01) and 
upregulation of  LPIN3 (1.23 ± 0.10 vs. 1.00 ± 0.04 AU, P < 0.05) were confirmed (Figure 3C). Among 
genes involved in phospholipid metabolism, the expression of  phospholipase family member D4 (PLD4) 
was significantly decreased (0.83 ± 0.06 vs. 1.00 ± 0.06 AU, P < 0.05) in TTA/TATA group as compared 
with the TT group (Figure 3C).
Plasma cytokines
Since the gene expression profile suggested that carriers of  the HSD17B13 variant might be character-
ized by decreased inflammation, we measured plasma concentrations of  cytokines (Figure 3D). Plasma 
concentrations of  IL-6 were significantly lower in the TTA/TATA group as compared with the TT group 
(9.0 ± 0.5 vs. 10.2 ± 0.5 pg/ml, P < 0.05) (Figure 3D).
Liver free fatty acids and their sources
Hepatic fatty acids are the major substrates for synthesis of  complex lipids, such as triacylglycerols and phos-
pholipids. They can be derived from the diet, adipose tissue lipolysis, and hepatic DNL (16). There were no 
Figure 2. Increased hepatic phospholipids in 
carriers of the HSD17B13 rs72613567 variant. 
Liver lipids are visualized as a volcano plot, in 
which y axes denote the –log10 of P value of the 
t test between individual lipid species in the 
TTA/TATA (n = 38) as compared with the TT 
group (n = 48) and x axes denote the log2 fold 
change of mean concentrations of an individual 
lipid species between the HSD17B13 groups. Dif-
ferences were tested using independent 2-sam-
ple Student’s t test. Each symbol denotes an 
individual lipid species. PC, phosphatidylcho-
line; PE, phosphatidylethanolamine; PI, phos-
phatidylinositol; LysoPC, lyso-phosphatidylcho-
line; Cer, ceramide; SM, sphingomyelin; HexCer, 
hexosylceramide; ChoE, cholesteryl ester; DAG, 
diacylglycerol; TG, triacylglycerol.
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Figure 3. Decreased hepatic inflammation in carriers of the HSD17B13 rs72613567 variant. (A) Volcano plot of differentially expressed genes in the livers 
of carriers (TTA/TATA, n = 36) as compared with noncarriers (TT, n = 50) of the HSD17B13 rs72613567 variant. The x axes denote log2 fold change and y axes 
denote the –log10 of the q value of expression of genes in the livers of carriers as compared with noncarriers. The number in green denotes the amount of 
significantly differentially expressed genes. The analysis was performed by limma. (B) Enrichment map of gene ontology (GO) pathways of differentially 
expressed genes in the livers of carriers as compared with noncarriers of the HSD17B13 variant. Data were analyzed using the enricher function in the 
clusterProfiler R package. The color of the bubbles denotes q values and size denotes the number of genes in the pathway. (C) Quantitative PCR analysis 
of hepatic gene expression in the TTA/TATA (green bars and circles, n = 42) groups as compared with the TT group (black bars and circles, n = 60). The 
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differences in free fatty acids (398 ± 17 vs. 382 ± 12 nmol/g for 16:0, 219 ± 11 vs. 195 ± 7 nmol/g for 18:0, 
196 ± 9 vs. 194 ± 8 nmol/g for 18:1, 86 ± 4 vs. 89 ± 4 nmol/g for 18:2 and 54 ± 3 vs. 54 ± 2 nmol/g for 20:4, 
respectively, NS) in the liver in the TTA/TATA group as compared with the TT group (Figure 4). The rate 
of  adipose tissue lipolysis, as determined by the rate of  appearance (Ra) of  glycerol, was similar between the 
HSD17B13 groups both in the basal state (2.92 ± 0.24 vs. 3.12 ± 0.16 μmol/kg.min, NS, Figure 4) and during 
euglycemic hyperinsulinemia (1.66 ± 0.19 vs. 1.63 ± 0.09 μmol/kg.min, NS, Figure 4). The rate of  hepatic 
DNL, as determined by the percentage of  newly synthesized palmitate in VLDL-triglyceride, was comparable 
in the TTA/TATA and the TT groups (7.5 ± 0.8 vs. 7.7 ± 0.8%, NS, Figure 4).
Hepatic glucose production and insulin sensitivity
The hepatic glucose production (Ra of  glucose) was similar in the basal state (2.82 ± 0.13 vs. 3.08 ± 0.14 
mg/kg FFM.min, Figure 4) and during euglycemic hyperinsulinemia (0.65 ± 0.20 vs. 0.74 ± 0.18 mg/kg 
FFM.min, Figure 4) in the TTA/TATA group as compared with the TT group.
Discussion
We found lower prevalence of  fibrosis (Figure 1 and Table 1) and increased concentration of  phospholipids 
in the livers of  subjects carrying the HSD17B13 rs72613567:TA variant compared with noncarriers (Figure 
2). Analysis of  the liver transcriptome using RNA-seq and qPCR revealed marked downregulation of  multi-
ple inflammation-related gene sets (Figure 3). Plasma concentrations of  the key proinflammatory cytokine, 
IL-6, were lower in carriers of  the HSD17B13 variant as compared with noncarriers (Figure 3). Metabolic 
pathways contributing to IHTG synthesis, including DNL and the rate of  in vivo lipolysis and hepatic insu-
lin sensitivity, were unaltered in carriers of  the HSD17B13 variant compared with noncarriers (Figure 4).
The prevalence of  fibrosis, the most important predictor of  mortality in NAFLD (17), was significant-
ly lower in carriers compared with noncarriers of  the HSD17B13 variant (Figure 1 and Table 1), consistent 
with the study of  Abul-Husn et al. (1) and that of  Pirola et al. in 356 patients with biopsy-proven NAFLD 
(3). In the latter 2 studies, as in the present study, the HSD17B13 variant was not associated with a change 
in steatosis (Figure 1) (1, 3). In a larger study comprising 756 adults with biopsy-proven NAFLD, Ma et al. 
found increased steatosis in carriers compared with noncarriers of  the HSD17B13 variant (rs72613567:TA) 
(2). Unlike previous studies, features of  nonalcoholic steatohepatitis (NASH) were similar in our data 
(Figure 1 and Table 1). This could reflect a smaller sample size compared with previous studies.
Concentrations of  hepatic phospholipids, including PCs and PEs, but not other lipids including tri-
glycerides, DAGs, or ceramides, were increased in variant allele carriers compared with noncarriers (Figure 
2). This lipid pattern is geometrically opposite to that seen in deficiency of  choline, an essential nutrient, in 
which concentrations of  PCs and PEs are decreased (18, 19). Dietary restriction of  choline predisposes to 
fatty liver in humans, and its daily requirements to prevent liver dysfunction are highly variable (18, 20, 21). 
In mice, dietary restriction of  choline and/or genetic inhibition of  hepatic PC synthesis lead to liver inflam-
mation, NASH (22), and liver failure (23). In contrast, increasing PC synthesis by choline treatment has been 
shown to prevent both sugar- and alcohol-induced cirrhosis in rats in carefully performed studies published in 
1949 (24). Moreover, dietary supplementation of  PC has been shown to protect against alcohol-induced liver 
fibrosis and cirrhosis in nonhuman primates, possibly by promoting collagen breakdown (25). Decreased 
expression of  a phospholipid degrading enzyme PLD4 (Figure 3C) suggests that the phospholipid surplus 
could be secondary to the reduced degradation of  phospholipids in HSD17B13 variant carriers as com-
pared with noncarriers. Phospholipids constitute the surface layer of  lipid droplets, and their excess could be 
hypothesized to enhance storage capacity of  lipid droplets, in keeping with increased hepatic expression of  
a key lipid droplet protein, LPIN3, in HSD17B13 variant carriers (Figure 3C). The present data thus raise 
the possibility that the HSD17B13 variant might protect against progressive liver disease, perhaps especially 
data were tested using independent 2-sample Student’s t test and are expressed relative to the TT group as mean ± SEM. *P < 0.05. ALOX5, arachidonate 
5-lipoxygenase; TRAF3, TNF receptor–associated factor 3; HIF1A, hypoxia-inducible factor 1 subunit α; TGFB2, TGF-β2; COL3A1, collagen type III α 1 chain; 
CHPT1, choline phosphotransferase 1; CEPT1, choline/ethanolamine phosphotransferase 1; PCYT1A, phosphate cytidylyltransferase 1; PEMT, phosphati-
dylethanolamine N-methyltransferase; PLA2G12A, phospholipase A2, group XIIA; PLCD3, phospholipase C δ 3; PLD4, phospholipase D family member 
4; ABCB4, ATP binding cassette subfamily B member 4; LPIN3, lipin 3. (D) Plasma concentrations of IL-1β, IL-6, IL-10, IFN-γ, and TNF-α in the TTA/TATA 
(green bars and circles, n = 45) groups as compared with the TT group (black bars and circles, n = 70). The data were analyzed using independent 2-sample 
Student’s t test and are expressed relative to the TT group as mean ± SEM. *P < 0.05.
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in choline-depleted individuals, by increasing synthesis and/or decreasing breakdown of  hepatic phospho-
lipids. The molecular mechanisms linking phospholipids and progression of  fibrosis are poorly understood, 
but at least in choline- and methionine-depleted models include altered redox status and inflammation (26). 
While these findings are of  interest, given the extensive literature on altered choline metabolism and liver 
disease (18–25), they do not prove cause and effect and call for further mechanistic studies.
Analysis of  the liver transcriptome in 86 subjects using RNA-seq revealed downregulation of  254 gene 
sets while only 2 gene sets were upregulated in carriers compared with noncarriers (Figure 3). The down-
regulated genes were predominantly key inflammatory genes, such as ALOX5 and TGFB2. In keeping with 
the gene expression data, plasma concentrations of  IL-6, a proinflammatory cytokine that has increased 
concentrations in NASH (27), were decreased in carriers of  the HSD17B13 variant as compared with non-
carriers (Figure 3D). These data are consistent with previous data on effects of  the HSD17B13 variant on 
the liver transcriptome in the study of  Pirola et al. who compared 8 carriers to 5 noncarriers (3).
Free fatty acids originating from lipolysis and DNL are two major pathways contributing to IHTG 
synthesis (16). Although steatosis was not different in the present study or studies by Abul-Husn et 
al. (1) or Pirola et al (3), pathways of  IHTG could still be different, as has been described for the 
PNPLA3 I148M gene variant (28). However, the HSD17B13 variant does not seem to alter either DNL 
or adipose tissue lipolysis when measured using state-of-the-art isotope techniques, including deuter-
ated water and glycerol.
Unlike NAFLD associated with the PNPLA3 I148M and the TM6SF2 E167K gene variants, common 
NAFLD is characterized by insulin resistance (29). This is the first study to our knowledge to quantify insu-
lin sensitivity using the euglycemic clamp technique combined with infusion of  tritiated glucose between 
Figure 4. Hepatic free fatty acids, de novo lipogenesis, adipose tissue lipolysis, and hepatic insulin sensitivity 
are similar in carriers and noncarriers of the HSD17B13 rs72613567 variant. (A) The concentrations of individual 
hepatic free fatty acids (TT, n = 48; TTA/TATA, n = 38) and (B) the rate of hepatic de novo lipogenesis (TT, n = 
67; TTA/TATA, n = 59) in the HSD17B13 groups. (C) The rate of appearances of glycerol in the basal state and (D) 
during euglycemic hyperinsulinemia in the TT (n = 40) and TTA/TATA (n = 12) groups. (E) The rate of appearances 
of glucose in the basal state and (F) during euglycemic hyperinsulinemia in the TT (n = 62) and TTA/TATA (n = 
43) groups. The data were analyzed using independent 2-sample Student’s t test and are shown as mean ± SEM. 
Black bars = TT; green bars = TTA/TATA. FFM, fat free mass.
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HSD17B13 variant allele carriers and noncarriers. No data on glucose and insulin concentrations were 
reported in studies by Abul-Husn et al. (1) or Ma et al. (2). Unlike the latter studies, in the study of  Pirola 
et al. (3), homozygous variant allele carriers were significantly less obese than the heterozygous subjects or 
noncarriers (3). We found that the HSD17B13 variant allele did not affect any measure of  insulin sensitivity. 
If  viewed from the perspective of  the effect of  choline deficiency on insulin sensitivity, previous studies in 
mice fed a choline-deficient diet, which induces steatosis and mild inflammation, showed that mice do not 
exhibit insulin resistance (30). Thus, the higher concentrations of  PCs and PEs in carriers than noncarriers 
of  the HSD17B13 variant would not be expected to change insulin sensitivity.
We conclude that carriers of  the HSD17B13 variant are protected against liver fibrosis and that they 
have phospholipid surplus in the liver and marked downregulation of  genes and plasma cytokines related 
to inflammation. Steatosis and pathways leading to steatosis, including DNL and lipolysis, are unchanged. 
All of  these features are geometrically opposite to those observed in choline-deficient models in mice and 
humans and suggest that HSD17B13 might be an attractive pharmaceutical target in liver disease.
Methods
Study subjects
Histology and lipid composition of  the human liver. A total of  485 subjects was included in the study, of  which 
202 subjects were recruited from patients undergoing laparoscopic bariatric surgery. Subjects were eligible 
if  they, after a phone interview and a separate clinical study visit (see below), met the following inclusion 
criteria: (a) age 18–75 years; (b) no known acute or chronic disease except for features of  the metabolic 
syndrome based on medical history, physical examination, and standard laboratory tests (complete blood 
count, serum creatinine, electrolyte concentrations); (c) alcohol consumption of  less than 20 g per day in 
women and less than 30 g per day in men; (d) no clinical or biochemical evidence of  other liver disease 
than NAFLD or clinical signs or symptoms of  inborn errors of  metabolism; and (e) no use of  drugs or 
toxins influencing liver steatosis. Subjects with diabetes were excluded from this cohort, as we wished to 
study the effect of  the HSD17B13 genotype at rs72613567 rather than that of  insulin resistance/diabetes 
and antidiabetic drugs on the human liver lipid metabolism.
Pathways of  hepatic triglyceride synthesis and insulin sensitivity. 283 subjects who were not undergoing 
bariatric surgery were studied to compare rates of  adipose tissue lipolysis, hepatic DNL and hepatic 
glucose production basally and during hyperinsulinemia using the same inclusion and exclusion criteria 
as described above.
All subjects were divided into groups based on their HSD17B13 genotype at rs72613567 (carriers of  
splice variant with adenine insertion, TTA/TATA, and noncarriers, TT).
Study designs
All subjects were invited to a clinical visit for metabolic characterization after an overnight fast. After 
anthropometric measurements (body weight, height, and waist circumference), an intravenous cannula was 
inserted in an antecubital vein. Blood was collected for measurement of  total blood counts, glycosylated 
hemoglobin (HbA1c), serum insulin, plasma glucose, LDL and HDL cholesterol, triglyceride, alanine amino-
transferase (ALT), AST, alkaline phosphatase (ALP), γ-glutamyltransferase (GGT), and albumin concentra-
tions and for genotyping of  PNPLA3 rs738409, TM6SF2 rs58542926, MBOAT7 rs641738, and HSD17B13 
rs72613567 as previously described (12–14). Genotype data were in Hardy-Weinberg equilibrium. Serum 
carbohydrate-deficient transferrin (CDT) and GGT-CDT combination were determined as biomarkers of  
alcohol consumption using previously established protocols (31).
Histology, transcriptome, and lipid composition of  the human liver. The patients undergoing bariatric sur-
gery underwent the metabolic study 1 week prior to surgery, during which the liver biopsy was taken (see 
below). The body weight of  these subjects did not differ between the time of  the metabolic study and 
surgery (129.6 ± 2.0 kg and 129.3 ± 2.2 kg, NS).
Pathways of  hepatic triglyceride synthesis and insulin sensitivity. The subjects in whom rates of  pathways 
contributing to IHTG synthesis and hepatic insulin sensitivity were measured participated in a visit at the 
metabolic study unit and in an imaging visit for measurement of  IHTG using proton magnetic resonance 
spectroscopy (see below) in addition to the metabolic characterization visit.
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Liver biopsy and liver histology
Routine wedge biopsy of  the liver was taken in the beginning of  the surgery. Part of  the biopsy was sent to 
an experienced liver pathologist for analysis of  liver histology in a blinded fashion according to the SAF 
score (32), and, if  available, another part was snap-frozen in liquid nitrogen for subsequent analysis of  
molecular lipids and transcriptome (see below).
Hepatic lipidomic and free fatty acid analysis
Hepatic lipidomic analyses were performed using a Q-TOF Premier (Waters) quadrupole time-of-flight 
mass spectrometer combined with an Acquity Ultra Performance LC (Waters) liquid chromatography, as 
described in the Supplemental Methods. Hepatic free fatty acids were analyzed using an Agilent 6890 gas 
chromatograph equipped with a split/splitless injector (Agilent Technologies), cryogenic dual-stage modu-
lator, and time-of-flight mass spectrometer (Leco Corp.) as described previously (12).
Hepatic transcriptome
Hepatic transcriptome was assessed using RNA-seq (Supplemental Table 11). The samples were prepared 
using the Illumina TruSeq RNA Sample preparation kit (Illumina), and sequencing was performed using a 
paired-end 101-bp protocol on the HiSeq2000 platform (Illumina) as described previously (13). The output 
reads were aligned to human reference genome (GRCh38) using STAR (v2.4.1a), and uniquely mapped 
fragments were counted against genomic features defined by the Gencode v22 annotation using Feature-
Counts software as described previously (13). The data are included in the Supplemental Methods.
mRNA expression of different genes was analyzed by qPCR. RNA from liver tissue biopsies was iso-
lated using the RNeasy Mini Kit (Qiagen). cDNA synthesis was performed using the SuperScript VILO 
reverse transcriptase kit (Invitrogen) according to the manufacturer’s protocol. qPCR was carried out with 
the LightCycler 480 SYBR Green I Master (Roche) and gene-specific primers (Supplemental Table 10). 
Relative gene expression was calculated from the Cp (second derivative method) values. Data were normalized 
to the geometric mean of house keeping controls, β-actin, and acidic ribosomal phosphoprotein P0, 36B4.
Plasma cytokines
Concentrations of  plasma IL-1β, IL-6, IL-10, IFN-γ, and TNF-α were measured by Q-Plex Human Cyto-
kine P1 6-Plex ELISA assay (Quansys Biosciences) according to the manufacturer’s instructions.
IHTGs
IHTG content was measured by proton magnetic resonance spectroscopy (1H-MRS) using 1.5T Siemens 
Avantofit and jMRUI v5.2 software with an AMARES algorithm as described previously (33).
Hepatic DNL
Fasting hepatic DNL was measured from incorporation of  deuterium of  2H2O in plasma water (Finnigan 
GasBench-II, Thermo Fisher Scientific) into palmitate in VLDL-triglyceride using gas chromatography/
mass spectrometry with monitoring ions with mass-to-charge ratios (m/z) of  270 (M+0) and 271 (M+1) 
(34). VLDL was isolated by ultracentrifugation as described previously (33).
Adipose tissue lipolysis
The rate of  whole-body lipolysis (rate of  appearance [Ra] of  glycerol) and effect of  insulin on lipolysis were 
determined by infusing [2H5]glycerol for 120 minutes before (0–120 min) and for 120 minutes during eugly-
cemic hyperinsulinemia maintained using the euglycemic hyperinsulinemic clamp technique as previously 
described (35). The duration of  the insulin infusion was 120 minutes (120–240 min), and rate of  the contin-
uous insulin infusion was 0.4 mU/kg per minute (36). The low insulin infusion rate was chosen to optimize 
the conditions for detecting changes in lipolysis, which is half-maximally suppressed already at insulin 
concentrations of  13 mU/L in normal subjects (37). The concentrations needed to inhibit hepatic glucose 
production or stimulate glucose disposal in normal subjects are approximately 50 mU/L and approximate-
ly 100 mU/L (38). Before start of  the infusions, two 18-gauge catheters (Venflon, Viggo-Spectramed) were 
inserted, one in a left antecubital vein and another retrogradely in a heated (+65 °C) dorsal hand vein for 
sampling of  arterialized venous blood for insulin (0, 120, 180, and 240 min) and concentrations of  glycerol 
and its isotopic enrichment (0, 100, 120, 130, 140, 150, 180, and 240 min).
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Hepatic glucose production and insulin sensitivity
Hepatic glucose production (Ra of glucose) and insulin sensitivity of glucose Ra were assessed by using the eugly-
cemic hyperinsulinemic clamp technique combined with infusion of [3-3H]glucose as described previously (39). 
Because glucose Ra is more sensitive to suppression by insulin than stimulation of muscle glucose uptake (38), 
we chose a low insulin infusion rate (0.3 mU/kg per minute) to accurately quantify interindividual variation in 
hepatic insulin sensitivity. Glucose Ra were calculated using Steele’s non–steady-state equations (40).
Statistics
The Kolmogorov-Smirnov test was used to test the normality of  continuous variables. The independent 
2-sample 2-tailed Student’s t test and Mann-Whitney U test were used to compare normally and nonnor-
mally distributed data, respectively. Normally distributed data were reported in mean ± SEM, while non-
normally distributed data were reported as medians followed by interquartile ranges. Pearson’s χ2 test was 
used to evaluate if  the distribution of  categorical variables differed between the groups.
For the lipidomics analyses, data were log2 transformed and the mean values were compared between 
groups based on HSD17B13 genotype using unpaired 2-tailed t tests. Lipidomics data were visualized using 
a volcano plot, in which the y axes denote the –log10 transformed P values and the x axes denote the log2 
fold changes in individual lipid concentrations in the TTA/TATA group as compared with the TT group.
Differential expression analyses were conducted to investigate the hepatic transcriptome changes between 
the HSD17B13 variant allele carriers and noncarriers. Prior to differential expression analyses, normalization 
factors were calculated from the raw read counts using trimmed mean of  M values (TMM) normalization (41) 
to account for library size variation between samples, and only genes with sufficiently large read counts, i.e., 
minimum count in at least 1 sample = 10 and minimum total count across samples = 15, were retained, and 
both procedures were implemented in the edgeR R package (42). To remove unwanted noise from the gene 
expression data, unknown and unmeasured artifacts were estimated using svaseq (43) with read counts as 
input and modeling the gene variant, sex, and age as known variables. The association between gene expres-
sion and each gene variant was examined using the limma approach to RNA-seq data (44, 45) using read 
counts adjusted with precision weights from voom (44) in linear modeling (lmFit function) with sex, age, and 
surrogate variables from the above svaseq step as covariates and applying the empirical Bayes smoothing to 
standard errors (eBayes function) (46). Q values were estimated from the P values separately for each gene 
variant analysis using the q value R package (ref. 47; http://github.com/jdstorey/qvalue), and q < 0.05 was 
used as the threshold for calling a gene differentially expressed. The gene set enrichment analysis was con-
ducted using the enricher function in the clusterProfiler R package (48) using the differentially expressed genes 
as the input and analyzing the enrichments for upregulated and downregulated genes separately. The results 
were visualized using the emapplot and heat plot functions in the enrichplot R package (ref. 49; https://
github.com/GuangchuangYu/enrichplot). Gene sets with q < 0.05 were considered significantly enriched. 
The GO gene sets used in the enrichment analyses were obtained from the Molecular Signatures Database 
(MSigDB) using the msigdbr function (https://CRAN.R-project.org/package=msigdbr). All differential 
expression and gene set enrichment analyses were conducted in R (version 3.5.2). Other statistical analyses 
were performed by using IBM SPSS Statistics 22.0.0.0 version, Microsoft Excel 2016, and GraphPad Prism 
7.0 for Mac OS X. A 2-sided P value of  less than 0.05 indicated statistical significance.
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